Pauls, MMH;
Binnie, LR;
Benjamin, P;
Betteridge, S;
Clarke, B;
Dhillon, M-PK;
Ghatala, R;
Hainsworth, FAH;
Howe, FA;
Khan, U;
et al.
Pauls, MMH; Binnie, LR; Benjamin, P; Betteridge, S; Clarke, B; Dhillon, M-PK; Ghatala, R; Hainsworth, FAH; Howe, FA; Khan, U; Kruuse, C; Madigan, JB; Moynihan, B; Patel, B; Pereira, AC; Rostrup, E; Shtaya, ABY; Spilling, CA; Trippier, S; Williams, R; Young, R; Barrick, TR; Isaacs, JB; Hainsworth, AH
(2022)
The PASTIS trial: Testing tadalafil for possible use in vascular cognitive impairment.
Alzheimers & Dementia, 18 (12).
pp. 2393-2402.
ISSN 1552-5260
https://doi.org/10.1002/alz.12559
SGUL Authors: Hainsworth, Atticus Henry Isaacs, Jeremy Barrick, Thomas Richard Howe, Franklyn Arron Benjamin, Philip
|
PDF
Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (1MB) | Preview |
|
![]() |
Microsoft Word (.docx) (Supporting information)
Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (74kB) |
|
|
PDF
Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (913kB) | Preview |
Abstract
Introduction There are few randomized clinical trials in vascular cognitive impairment (VCI). This trial tested the hypothesis that the PDE5 inhibitor tadalafil, a widely used vasodilator, increases cerebral blood flow (CBF) in older people with symptomatic small vessel disease, the main cause of VCI. Methods In a double-blind, placebo-controlled, cross-over trial, participants received tadalafil (20 mg) and placebo on two visits ≥7 days apart (randomized to order of treatment). The primary endpoint, change in subcortical CBF, was measured by arterial spin labelling. Results Tadalafil increased CBF non-significantly in all subcortical areas (N = 55, age: 66.8 (8.6) years) with greatest treatment effect within white matter hyperintensities (+9.8%, P = .0960). There were incidental treatment effects on systolic and diastolic blood pressure (–7.8, –4.9 mmHg; P < .001). No serious adverse events were observed. Discussion This trial did not identify a significant treatment effect of single-administration tadalafil on subcortical CBF. To detect treatment effects may require different dosing regimens.
Item Type: | Article | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Additional Information: | © 2022 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. | |||||||||
Keywords: | 1109 Neurosciences, 1103 Clinical Sciences, Geriatrics | |||||||||
SGUL Research Institute / Research Centre: | Academic Structure > Molecular and Clinical Sciences Research Institute (MCS) | |||||||||
Journal or Publication Title: | Alzheimers & Dementia | |||||||||
ISSN: | 1552-5260 | |||||||||
Dates: |
|
|||||||||
Publisher License: | Publisher's own licence | |||||||||
Projects: |
|
|||||||||
URI: | https://openaccess.sgul.ac.uk/id/eprint/113918 | |||||||||
Publisher's version: | https://doi.org/10.1002/alz.12559 |
Statistics
Actions (login required)
![]() |
Edit Item |